
The Palantir NHS contract that runs the health service’s federated data platform will end in March 2029, the government has confirmed. Health innovation minister James Frith told the Commons on 16 November 2026 that a fresh procurement will follow, with British companies given what he called “a fair crack” at one of the most controversial technology deals in NHS history.
The announcement settles months of speculation about the future of the federated data platform (FDP), the system NHS trusts in England use to pull together data on waiting lists, theatre schedules, discharges and stock. It also sets the clock running on a contest that a group of UK firms is already preparing to enter.
Frith, the MP for Bury North, said government priorities had “moved on” since the platform was procured in 2023, and that a new process was needed to meet an “additional appetite for new capabilities, potentially backed by UK sovereign capabilities”, Digital Health News reported.
When does the Palantir NHS contract end?
The contract will end in March 2029. Market engagement with potential suppliers is due to begin in January 2027, with formal procurement starting in the second half of 2027. The whole process is expected to take around 18 months.
Palantir’s deal began in March 2024 on an initial three-year term, with options to extend it by up to four further years. Campaigners had pressed ministers to walk away at a break clause in March 2027. Instead, the government has opted for a planned handover two years later, a route ministers say avoids disruption to services that now depend on the platform.
Frith said the government would make sure the “necessary conditions” were in place to move to a new FDP without disrupting patient care. In the meantime, he urged NHS organisations to “make full use of the capabilities available on the FDP to improve their performance and productivity”, including trusts that have yet to sign up.
Why the Palantir deal has been so contentious
Few NHS IT contracts have drawn as much scrutiny. Palantir’s route into the health service began with a £1 contract for a Covid-19 data platform in 2020, which grew into the £330 million FDP contract awarded by NHS England in November 2023.
Since then, objections have come from several directions. The British Medical Association called on doctors earlier this year to reject using the platform, Sheffield became the first council to formally oppose the contract in July, and campaigners have raised concerns about the company’s ethics. Analysis by the Financial Times suggested the benefits attributed to the FDP were very uneven across trusts, and last week NHS England removed a claim that 137 trusts were benefiting from the technology after questions about its accuracy.
The minister also pointed to the recent global Microsoft outage, which disrupted GP practices and NHS 111 referrals, as evidence of “the importance of avoiding overdependence” on a single technology supplier. London Journal examined that episode in our analysis of Britain’s reliance on one supplier.
Amnesty International UK welcomed the decision. Tom Guha, a crisis campaigner at the charity, called it a “victory for healthcare workers, patients and campaigners”, adding: “The next two years must be about extracting Palantir from our NHS, not allowing it to become more deeply embedded.”
Who could replace Palantir in the NHS?
Frith said the new procurement would open “new, exciting prospects for UK-based companies”, although international suppliers will also be invited to tender. “Within a fair and open competition framework, we will use our purchasing power to create routes to market for innovative companies, giving British start-ups a fair crack at NHS contracts,” he said.
The field is already taking shape. The Drystone Health AI Collaboration, a consortium of more than 20 UK companies including Black Pear Software, VitalHub UK, Patients Know Best, Interweave Digital and IMS Maxims, has announced plans to bid. London-based Quantexa, which competed for the original contract, is understood to be preparing another attempt, while Oracle Health, a finalist in 2023, is seen as a potential contender.
Lisa Riley of VitalHub UK said the contest “shouldn’t just be about competing with Palantir”, but about showing that the UK “already has much of the talent, technology and healthcare expertise needed to build what comes next”. The Financial Times has reported that the government is drawing up a new definition of a UK supplier for procurement purposes, while Palantir could argue its case by pointing to its British workforce.
What the Palantir decision means for NHS patients
For patients, nothing changes immediately. The platform will keep running until 2029, and the government has promised a transition that does not interrupt care. Frith said the design of the next system and its contracts would be “informed by frontline NHS teams, patients and the public”, a nod to the trust questions that have dogged the current deal.
Alongside the procurement, the minister set out wider plans: common open data standards so information can flow consistently across health and care, work with several providers to tackle data fragmentation in maternity services, and a plan, due in 2027, to implement the 44 recommendations of the National Commission into the Regulation of AI in Healthcare on cyber security, interoperability and transparency.
What happens next
The next milestone is January 2027, when the NHS begins sounding out the market. How the government defines a “UK supplier”, and whether trusts heed calls from campaigners not to expand their use of the current platform, will shape the contest well before formal bids arrive. For patients, the bigger question is whether a new system can deliver the joined-up data the NHS has long promised while winning the public confidence the current one never fully secured.
For more NHS and medical news, see the London Journal health section.
































